Sakar Healthcare Limited

SAKAR

INE732S01012

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 12:43:58 10/09/2024 BST			5-day change	1st Jan Change
340.40 ^INR	+5.60%		+4.47%	-14.91%

08-13	Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI
05-21	Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Sakar Healthcare Limited announced that it has received INR 148.5 million in funding from HBM Partners Ltd.

May 13, 2021

Sakar Healthcare Limited (NSEI:SAKAR) announced that it has received INR 148.5 million in a round of funding on May 14, 2021. The transaction included participation from HBM Cobra India, a fund managed by HBM Partners Ltd.

Latest news about Sakar Healthcare Limited

Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	08-13	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-21	CI
Sakar Healthcare Ltd Receives EU GMP Approval Dated 5th March 2024With A Validity of Three Years from Audited Date	03-06	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-10	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-06	CI
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited	02/08/23	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	26/05/23	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/02/23	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22/10/22	CI
Indian shares seen opening lower; U.S. jobs data in focus	07/10/22	RE
Sakar Healthcare Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	06/08/22	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	20/05/22	CI
Sakar Healthcare Limited Reports Earnings Results for the Full Year Ended March 31, 2022	20/05/22	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	08/02/22	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	29/10/21	CI
Sakar Healthcare's Fully-Integrated Anti-Cancer Formulation Unit, Now Starting with Research Laboratories	22/09/21	CI
Sakar Healthcare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	31/05/21	CI
Sakar Healthcare Limited announced that it has received INR 148.5 million in funding from HBM Partners Ltd.	13/05/21	CI
Sakar Healthcare Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	05/02/21	CI
Sakar Healthcare Limited Announces Executive Changes	28/10/20	CI
Sakar Healthcare Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	28/10/20	CI
Sakar Healthcare Limited Receives European Union GMP Approval for the Small Volume Parenteral Unit Manufacturing Liquid Injections & Lyophilized Injections	06/10/20	CI
Sakar Healthcare Limited Appoints Hemendrakumar Chamanlal Shah as an Independent Director	27/09/20	CI
Sakar Healthcare Limited Announces Resignation of Hardik P. Mehta as Independent Director	27/09/20	CI

Chart Sakar Healthcare Limited

Duration

Period

More charts

Company Profile

Sakar Healthcare Limited is an India-based pharmaceutical formulations company. The Company is engaged in manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablet, capsule, dry powder syrup, dry powder injections, liquid injectable (SVP) in ampoules, vials & lyophilized injections, oral solid dosages and research & development of above products. The Company's oncology products include oral solid dosage (tablet & capsule), liquid injection, lyophilized injection, active pharmaceutical ingredient (API), CDMO products and CRAMs. The Company's product portfolio includes approximately 175 formulations for the international markets, 292 registered brands under its own name in more than 24 therapeutic areas. It has a presence across the regions of Africa (Anglo & Francophone), SEASIA, CIS, Latin & Central America and in Europe. The Company has set up a research-driven vertically integrated with API for oncology formulation manufacturing unit.

Employees

325

Sector

Pharmaceuticals

Calendar

21/09/2024 - Annual General Meeting

More about the company